Association of TKIs and DOACs is common in cancer patients, to prevent venous thromboembolism, but TKIs’ influence upon P-gp and CYP3A4 affects DOAC (dabigatran, apixaban, rivaroxaban, edoxaban) plasmatic concentrations. The gene discussed is CYP3A4; the disease is venous thromboembolism.